M1FG
PTCT icon

Mach-1 Financial Group’s PTC Therapeutics PTCT Stock Holding History

Mach-1 Financial Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,893
Closed -$351K – 283
2025
Q1 		$351K Buy
+6,893
New +$344K 0.11% 156

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mach-1 Financial Group's PTCT Position: Q2 2025 in Review

Mach-1 Financial Group sold out of PTC Therapeutics (PTCT) in Q2 2025, closing a stake of 6,893 shares — an estimated $351K sold.

Mach-1 Financial Group first reported a position in PTCT in Q1 2025 and held it in 1 quarter. The position peaked at $351K in Q1 2025. 284 funds tracked by Wall St. Rank hold PTCT as of Q2 2025.

  • Mach-1 Financial Group reported no remaining PTC Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mach-1 Financial Group sold 6,893 PTC Therapeutics shares in Q2 2025, an estimated $351K.
  • Mach-1 Financial Group first reported a position in PTC Therapeutics in Q1 2025 and held it in 1 quarter.
  • Mach-1 Financial Group's PTC Therapeutics position peaked at $351K in Q1 2025.
  • 284 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2025.

Based on Mach-1 Financial Group's 13F filing for Q2 2025, filed 11 Aug 2025.